Journal
FUTURE MEDICINAL CHEMISTRY
Volume 5, Issue 12, Pages 1405-1421Publisher
FUTURE SCI LTD
DOI: 10.4155/fmc.13.107
Keywords
-
Categories
Funding
- Louisiana Cancer Research Consortium (LCRC)
- DoD [W81XWH-11-11-0105]
- AREA from the National Cancer Institute [R15CA159059]
Ask authors/readers for more resources
Ceramide serves as a central mediator in sphingolipid metabolism and signaling pathways, regulating many fundamental cellular responses. It is referred to as a tumor suppressor lipid', since it powerfully potentiates signaling events that drive apoptosis, cell cycle arrest, and autophagic responses. In the typical cancer cell, ceramide levels and signaling are usually suppressed by overexpression of ceramide-metabolizing enzymes or downregulation of ceramide-generating enzymes. However, chemotherapeutic drugs as well as radiotherapy increase intracellular ceramide levels, while exogenously treating cancer cells with short-chain ceramides leads to anticancer effects. All evidence currently points to the fact that the upregulation of ceramide levels is a promising anticancer strategy. In this review, we exhibit many anticancer ceramide analogs as downstream receptor agonists and ceramide-metabolizing enzyme inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available